Skip to search formSkip to main contentSkip to account menu

nintedanib

Known as: Intedanib, Methyl (3Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylidene)-2-oxo-2,3-dihydro-1H-indole-6-carboxylate, methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylate 
An orally bioavailable, indolinone-derived, receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities… 
National Institutes of Health

Related topics

Related topics

12 relations

Broader (3)

Antineoplastic AgentsEnzyme InhibitorsIndoles

Narrower (3)

BIBF 1120Multitargeted Tyrosine Kinase Inhibitor BIBF 1120vargatef
Inhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPositive Regulation of ApoptosisReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
BACKGROUND Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes… 
Highly Cited
2019
Highly Cited
2019
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
BACKGROUND Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic… 
Review
2019
Review
2019
Properties of FDA-approved small molecule protein kinase inhibitors.
  • R. Roskoski
  • Pharmacological Research
  • 2019
  • Corpus ID: 80625382
Review
2019
Review
2019
Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update.
  • R. Roskoski
  • Pharmacological Research
  • 2019
  • Corpus ID: 209435035
Highly Cited
2015
Highly Cited
2015
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis.
  • New England Journal of Medicine
  • 2015
  • Corpus ID: 35325078
Review
2015
Review
2015
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterised by fibrosis of the lung… 
Review
2015
Review
2015
Nintedanib: from discovery to the clinic.
Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor… 
Highly Cited
2014
Highly Cited
2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
BACKGROUND Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase… 
Review
2014
Review
2014
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Highly Cited
2014
Highly Cited
2014
Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis
The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the treatment of idiopathic pulmonary… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)